Jax DiEugenio

Ivonescimab plus chemotherapy met the primary PFS end point vs tislelizumab plus chemotherapy in advanced squamous NSCLC.

Inati-cel generated complete remissions and MRD negativity in CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.

Salvage transplant was not associated with long-term survival benefits in relapsed/refractory multiple myeloma.

The combination of sacituzumab govitecan and pembrolizumab improved PFS vs pembrolizumab plus chemotherapy in PD-L1–positive mTNBC.

Paolo Tarantino, MD, discusses adjuvant strategies, trial data, and risk stratification shaping HER2+ breast cancer care.

On-site adaptive manufacturing of LV20.19 resulted in a high complete response rate and favorable tolerability in relapsed/refractory mantle cell lymphoma.

Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for advanced metastatic prostate cancer.

Paolo Tarantino, MD, discusses the growing emphasis on anthracycline-sparing approaches for the treatment of HER2-positive breast cancer.

TLX101 was associated with a favorable safety profile and preliminary signs of clinical activity in patients with recurrent high-grade glioma.

Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for renal cell carcinoma.

Response-adapted treatment with nivolumab with or without rituximab produced responses in treatment-naive follicular lymphoma.

Daratumumab plus lenalidomide maintenance improved clinical outcomes vs lenalidomide monotherapy in multiple myeloma after transplant.

The EC approved glofitamab with gemcitabine/oxaliplatin for patients with relapsed or refractory diffuse large B-cell lymphoma, ineligible for ASCT.

Daratumumab reduced the risk of disease progression or death vs active monitoring in high-risk smoldering multiple myeloma.

Michael J. Morris, MD, discusses data from the PSMAfore trial that supported the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in mCRPC.

Subcutaneous nivolumab demonstrated comparable efficacy, safety, and tolerability to IV nivolumab in advanced clear cell renal cell carcinoma.

Michael J. Morris, MD, discusses the FDA expanded approval of lutetium Lu 177 vipivotide tetraxetan in PSMA-positive mCRPC.

The ZEISS INTRABEM 700 platform received 510(k) clearance from the FDA for use in neuro-oncology and breast cancer surgery.

Belzupacap sarotalocan demonstrated a favorable safety profile and early signs of biological activity in patients with NMIBC.

The European Commission approved subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma, regardless of transplant eligibility.

Jennifer Chan, MD, underscores the importance of early NET diagnosis in young adult and pediatric patients.

Rachel N. Grisham, MD, discusses the preliminary results of avutometinib plus defactinib in mesonephric and mesonephric-like cancers.

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.

Obe-cel showed higher response rates and longer survival vs non–CAR T therapies in adults with R/R B-ALL.

TDI01, a selective ROCK2 inhibitor, generated responses and clinical benefit in patients with cGVHD.

CHMP recommends EU approval of acalabrutinib plus chemoimmunotherapy for untreated mantle cell lymphoma.

Relacorilant plus nab-paclitaxel demonstrated improved PFS and OS in platinum-resistant ovarian cancer.

Jeffrey Zonder, MD, emphasizes the importance of identifying MGUS and evaluating nonspecific symptoms to improve the detection of multiple myeloma.

Kelly E. McCann, MD, discusses mentorship, sponsorship, and work-life balance in oncology, highlighting strategies for supporting women in the field.

Tisotumab vedotin has received Japanese approval for advanced cervical cancer following chemotherapy.